No­var­tis posts land­mark CAR-T da­ta as head-to-head ri­val­ry with Kite Phar­ma looms

Vas­ant Narasimhan, chief med­ical of­fi­cer of No­var­tis AG, looks on dur­ing a Jan­u­ary 2017 news con­fer­ence in Basel  Michele Lim­i­na/Bloomberg

No­var­tis’ pi­o­neer­ing CAR-T drug CTL019 (ti­s­agen­le­cleu­cel) scored high in treat­ing dif­fuse large B-cell lym­phoma (DL­B­CL), spot­light­ing num­bers that will like­ly al­low the phar­ma gi­ant to plunge head-to-head in the mar­ket against its main ini­tial ri­val, Kite Phar­ma. But No­var­tis al­so found it­self de­fend­ing its man­u­fac­tur­ing op­er­a­tions Wednes­day morn­ing, as an­a­lysts ze­roed in on a num­ber of pa­tients who couldn’t be treat­ed in the study.

The fig­ures — drawn from its ea­ger­ly an­tic­i­pat­ed Phase II JULI­ET study — that will at­tract every­one’s at­ten­tion first: At three months the over­all re­sponse rate hit 45% among 23 of 51 pa­tients eval­u­at­ed with an im­pres­sive 37% achiev­ing a com­plete re­sponse and 8% achiev­ing a par­tial re­sponse. And those CRs con­tin­ued be­yond the three months to the da­ta cut­off in prep­ping for the an­nounce­ment, of­fer­ing a glimpse of dura­bil­i­ty that will help make No­var­tis’ case.

“For us as a med­ical com­pa­ny and from my or­ga­ni­za­tion’s stand­point, we want to have a dra­mat­ic im­pact,” No­var­tis $NVS chief med­ical of­fi­cer Vas Narasimhan tells me. “This is, of course, trans­for­ma­tive… It gives us the con­vic­tion to move ahead.”

Narasimhan in par­tic­u­lar high­light­ed ear­ly ev­i­dence of per­sis­tence for this ther­a­py, which will be cru­cial to dif­fer­en­ti­at­ing their drug from all the CAR-T ther­a­pies to come, from any an­gle.

The best rea­son to sug­gest why CTL019 could be a stand­out, he says, points to their drug’s use of the 4-1BB cos­tim­u­la­to­ry do­main, dis­tin­guished from the CD28 do­main used by Kite’s ri­val drug and Juno’s ini­tial lead ther­a­py, now scrapped in fa­vor of a drug that us­es 4-1BB. That 4-1BB do­main may ex­plain why the ini­tial ramp up of T cell ex­pres­sion is slight­ly slow­er, adding to longterm per­sis­tence. And it may al­so ex­plain No­var­tis’ rel­a­tive­ly clean safe­ty pro­file, with no ma­jor is­sues (so far) re­lat­ed to neu­ro­tox­i­c­i­ty, which will like­ly be giv­en care­ful scruti­ny at the FDA.

All that, though, has yet to be de­ter­mined.

Purists hate cross-tri­al com­par­isons, not­ing hard-to-score com­par­isons in the pa­tients stud­ied. But Wall Street’s first re­sponse will be to line up the da­ta from the phar­ma gi­ant against the num­bers for Kite’s KTE-C19 (axi­cab­ta­gene ciloleu­cel) at 3 months. Their drug hit an ORR of 39% among 51 pa­tients, with 33% achiev­ing a com­plete re­sponse — com­pa­ra­ble, though, mar­gin­al­ly less sig­nif­i­cant re­sults that will leave these two com­pa­nies bat­tling it out.

Narasimhan de­clined to touch my ques­tion about com­par­ing num­bers in the piv­otal stud­ies, which was to be ex­pect­ed. But Twit­ter was abuzz this morn­ing.

As ex­pect­ed, cy­tokine re­lease syn­drome was com­mon, with 57% ex­pe­ri­enc­ing CRS — al­though no one died from it. No deaths were at­trib­uted to the drug.

Kite’s num­bers have ma­tured be­yond that to the 6-month mark, slip­ping slight­ly but re­main­ing strong­ly com­pet­i­tive, as Kite CEO Arie Bellde­grun pre­dict­ed it would. And af­ter the JULI­ET da­ta were ini­tial­ly re­leased in an ab­stract ear­ly Wednes­day, cir­cu­lat­ing on Twit­ter, Kite’s shares jumped 6% af­ter in­vestors got a chance to eval­u­ate how the two drugs stacked up.

No­var­tis will get the first crack at an ap­proval for chil­dren with acute lym­phoblas­tic leukemia, with an FDA ex­pert pan­el slat­ed for Ju­ly 12. And with a pri­or­i­ty re­view, the agency is com­mit­ted to a quick re­sponse with a de­ci­sion due lat­er this year. Kite is about two months be­hind with a PDU­FA date of No­vem­ber 29.

An­oth­er area that No­var­tis, Kite and any fu­ture ri­vals will com­pete on is man­u­fac­tur­ing time.

Says Narasimhan: “Vein-to-vein time (the stretch from ex­tract­ing cells to get­ting them back in as a ther­a­py) we ex­pect to have in the range of 20 days. We were slow­er in the clin­i­cal tri­als,” with the man­u­fac­tur­ing arm bring­ing that down from 29 days.

Cowen got the dis­cus­sion about man­u­fac­tur­ing start­ed Wednes­day morn­ing by not­ing the ab­stract’s fig­ures on pa­tients in the study who nev­er made it to the in­fu­sion point. No­var­tis re­spond­ed with a state­ment, not­ing that they had fac­tored in a high dropout rate due to the very ad­vanced stage of an ag­gres­sive dis­ease and the rapid de­te­ri­o­ra­tion you would ex­pect in their sta­tus.

An­a­lysts al­so not­ed that a num­ber of pa­tients nev­er were treat­ed be­cause of man­u­fac­tur­ing prob­lems — a po­ten­tial­ly se­ri­ous sna­fu. But No­var­tis says it is get­ting a bet­ter han­dle on that and down­played the is­sue, adding:

 On­ly 6% (9 of 141) of en­rolled pa­tients were dis­con­tin­ued due to in­abil­i­ty to man­u­fac­ture an ad­e­quate dose of CART cells. Over the course of JULI­ET, with con­tin­u­ous process im­prove­ments, man­u­fac­tur­ing suc­cess rate im­proved to 97% for the last 30 pa­tients.

In JULI­ET, pa­tients could re­ceive bridg­ing chemother­a­py, re­flect­ing the ag­gres­sive na­ture of dis­ease in pa­tients with r/r DL­B­CL, so even pa­tients in poor con­di­tion could be en­rolled and in­fused. The cry­op­re­served leuka­phere­sis used in JULI­ET gives physi­cians the flex­i­bil­i­ty to sched­ule aphere­sis at a time that is in the best in­ter­est of their pa­tients, in­clud­ing times far in ad­vance of man­u­fac­tur­ing. The tri­al de­sign and pop­u­la­tion in­fused re­flects the re­al world chal­lenges in treat­ing pa­tients with an ag­gres­sive can­cer such as r/r DL­B­CL.

As for man­u­fac­tur­ing, we are con­fi­dent we will be able to meet the re­quired man­u­fac­tur­ing de­mands mov­ing for­ward.

The ac­tu­al cell pro­cess­ing time is 10-12 days. We an­tic­i­pate that the time from man­u­fac­ture start to prod­uct re­lease (in­clud­ing Qual­i­ty as­sess­ments) will be 22 days at the time of com­mer­cial launch. We have a rig­or­ous qual­i­ty as­sess­ment process to en­sure a GMP com­pli­ant prod­uct is re­leased to pa­tients.

Sig­nif­i­cant­ly, Kite CMO David Chang told me at AS­CO that they have vein-to-vein down to about 17 days, and would still like to shave a few days off that.

No­tably, No­var­tis’ man­u­fac­tur­ing chief for CAR-T re­cent­ly re­signed to take a sim­i­lar job at Seat­tle Ge­net­ics, rais­ing con­cerns with­in the phar­ma gi­ant’s R&D op­er­a­tions that the con­tin­u­ing ex­o­dus of ex­ecs out of No­var­tis — par­tic­u­lar­ly fol­low­ing last sum­mer’s re­or­ga­ni­za­tion — could ham­per its per­for­mance.

No­var­tis ex­ecs, though, have in­sist­ed that the multi­na­tion­al com­pa­ny is com­plete­ly com­mit­ted to mak­ing this all work com­mer­cial­ly, not­ing their lead role in the field.

An­a­lysts have been de­bat­ing for months now how the com­pe­ti­tion will shake out. The lead CAR-T at Juno im­plod­ed last year af­ter it killed five pa­tients due to cere­bral ede­ma. Then Kite rat­tled the mar­ket re­cent­ly with the news that one of its pa­tients al­so died from cere­bral ede­ma. Some have the­o­rized that the added safe­ty threat could be due to the dif­fer­ent cos­tim­u­la­to­ry do­mains used in the drug, with Kite and Juno’s first lead us­ing CD28 and No­var­tis fo­cused on 4-1BB. It’s nev­er been es­tab­lished, though, as re­searchers con­tin­ue to gain new in­sights on the best way to de­sign these CAR-Ts.

No­var­tis has made CTL019 one of its top on­col­o­gy pro­grams, push­ing hard to gain first-mar­ket ad­van­tage for a new kind of can­cer treat­ment that reengi­neers pa­tients cells in­to a ther­a­py. Its best ear­ly promise lies in liq­uid tu­mors with in­ves­ti­ga­tors work­ing to tack­le a broad slate of these can­cers. Next stop: find­ing bet­ter ways to go af­ter sol­id tu­mors with this tech­nol­o­gy. Be­hind that, Cel­lec­tis and oth­ers will try to de­vel­op off-the-shelf ther­a­pies that can be di­rect­ly ad­min­is­tered to pa­tients.

Narasimhan al­so men­tioned that the phar­ma gi­ant has been work­ing on freez­ing cells for lat­er use, per­haps prepar­ing ther­a­pies that can be used at a lat­er stage, if a pa­tient needs them to bat­tle drug re­sis­tance. How that sort of op­er­a­tion could be squared with pay­ers, though, he freely ad­mits will be a com­plex chal­lenge.

This first round of da­ta marks the cut­ting edge of the com­pe­ti­tion. There’s much, much more to come.

A fa­vorite in Alex­ion’s C-suite is leav­ing, and some mighty sur­prised an­a­lysts aren’t the least bit hap­py about it

Analysts hate to lose a biotech CFO they’ve come to trust and admire — especially if they’re being blindsided by a surprise exit.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

David Grainger [file photo]

'Dis­con­nect the bas­tard­s' — one biotech's plan to break can­cer cell­s' uni­fied de­fens­es

Chemotherapy and radiotherapy are the current gladiators of cancer treatment, but they come with well-known limitations and side-effects. The emergence of immunotherapy — a ferocious new titan in oncologist’s toolbox — takes the brakes off the immune system to kill cancer cells with remarkable success in some cases, but the approach is not always effective. What makes certain forms of cancer so resilient? Scientists may have finally pieced together a tantalizing piece of the puzzle, and a new biotech is banking on a new approach to fill the gap.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

While No­var­tis ban­ish­es Zol­gens­ma scan­dal scars — Bio­gen goes on a Spin­raza 'of­fen­sive'

While Novartis painstakingly works to mop up the stench of the data manipulation scandal associated with its expensive gene therapy for spinal muscular atrophy (SMA) Zolgensma— rival Biogen is attempting to expand the use of its SMA therapy, Spinraza. 

The US drugmaker $BIIB secured US approval for Spinraza for use in the often fatal genetic disease in 2016. The approval covered a broad range of patients with infantile-onset (most likely to develop Type 1) SMA. 

Jason Kelly. Mike Blake/Reuters via Adobe

Eye­ing big ther­a­peu­tic push, Gink­go bags $290M to build a cell pro­gram­ming em­pire

Ginkgo Bioworks is on a roll. Days after publicizing a plan to nurture new startups via partnerships with accelerators Y Combinator and Petri, the Boston biotech says it has raised another $290 million for its cell programming platform to reach further and wider.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Speak­er Nan­cy Pelosi to un­veil bill for fed­er­al­ly ne­go­ti­at­ed drug prices

After months of buzz from both sides of the aisle, Speaker Nancy Pelosi will today introduce her plan to allow the federal government to negotiate prices for 250 prescription drugs, setting up a showdown with a pharmaceutical industry working overtime to prevent it.

The need to limit drug prices is a rare point of agreement between President Trump and Democrats, although the president has yet to comment on the proposal and will likely face pressure to back a more conservative option or no bill at all. Republican Senator Chuck Grassley is reportedly lobbying his fellow party members on a more modest proposal he negotiated with Democratic Senator Ron Wyden in July.

Jeff Kindler's Cen­trex­ion re­news bid to make pub­lic de­but

Jeffrey Kindler’s plan to take his biotech — which is developing a slate of non-opioid painkillers — public, is back on.

The Boston based company, led by former Pfizer $PFE chief Kindler, originally contemplated a $70 million to $80 million IPO last year— but eventually postponed that strategy. On Wednesday, the company revived its bid to make a public debut in a filing with the SEC — although no pricing details were disclosed.

Zachary Hornby. Boundless

'A fourth rev­o­lu­tion in can­cer ther­a­pies': ARCH-backed Bound­less Bio flash­es big check, makes big­ger promis­es in de­but

It was the cellular equivalent of opening your car door and finding an active, roaring engine in the driver seat.

Scientists learned strands of DNA could occasionally appear outside of its traditional home in the nucleus in the 1970s, when they appeared as little, innocuous circles on microscopes; inexplicable but apparently innate. But not until UC San Diego’s Paul Mischel published his first study in Science in 2014 did researchers realize these circles were not only active but potentially overactive and driving some cancer tumors’ superhuman growth.

It’s fi­nal­ly over: Bio­gen, Ei­sai scrap big Alzheimer’s PhI­I­Is af­ter a pre­dictable BACE cat­a­stro­phe rais­es safe­ty fears

Months after analysts and investors called on Biogen and Eisai to scrap their BACE drug for Alzheimer’s and move on in the wake of a string of late-stage failures and rising safety fears, the partners have called it quits. And they said they were dropping the drug — elenbecestat — after the independent monitoring board raised concerns about…safety.

We don’t know exactly what researchers found in this latest catastrophe, but the companies noted in their release that investigators had determined that the drug was flunking the risk/benefit analysis.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 59,900+ biopharma pros reading Endpoints daily — and it's free.

Mer­ck helps bankroll new part­ner Themis' game plan to fin­ish the chikun­gun­ya race and be­gin on­colyt­ic virus quest

As Themis gears up for a Phase III trial of its chikungunya vaccine, the Vienna-based biotech has closed out €40 million ($44 million) to foot the clinical and manufacturing bills.

Its heavyweight partners at Merck — which signed a pact around a mysterious “blockbuster indication” last month — jumped into the Series D, led by new investors Farallon Capital and Hadean Ventures. Adjuvant Capital also joined, as did current investors Global Health Investment Fund, aws Gruenderfonds, Omnes Capital, Ventech and Wellington Partners Life Sciences.